VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1826-1834

  Minderman, Hans ^a   O'Loughlin, Kieran L ^a   Pendyala, Lakshmi ^a   Baer, Maria R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; TOPOTECAN;

ACUTE LEUKEMIA; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERIDINES; PYRIDINES;

EID: 1842532997     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0914-3     Document Type: Article

References (39)

1. Gottesman, M. M., Fojo, T., and Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2: 48-58, 2002.
2. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 26: 385-427, 1993.
3. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science (Wash. DC), 258: 1650-1654, 1992.
4. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
5. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
6. Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S. A., and Kruh, G. D. Expression of multidrug resistance-associated protein in NIH-3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res., 55: 5342-5347, 1995.
7. Honjo, Y., Hrycyna, C. A., Yan, Q-W., Medina-Perez, W. Y., Robey, R. W., Van de Laar, A., Litman, T., Dean, M., and Bates, S. E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res., 61: 6635-6639, 2001.
8. Suvannasankha, A., Minderman, H., O'Loughlin, K. L., Nakanishi, T., Greco, W. R., Ross, D. D., and Baer, M. R. Breast cancer resistance protein: Discordance between expression and function in acute myeloid leukemia. Blood, 100: 67a, 2002.
9. Plasschaert, S. L. A., de Bont, E. S. J. M., Kamps, W. A., van der Kolk, D. M., Morisaki, K., Scheffer, G. L., Scheper, R. J., Vellenga, E., and de Vries, E. G. E. Functional activity of breast cancer resistance protein (BCRP) in acute lymphoblastic leukemia. Leukemia (Baltimore), 17: 662, 2003.
10. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C., Floot, B. G., and Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59: 4559-4563, 1999.
11. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946, 1999.
12. Scheffer, G. L., Winjngaard, L. J., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J. L. M., Clevers, H. C., and Scheper, R. J. The drug resistance-related protein LRP is the major vault protein. Nat. Med., 1: 578-582, 1995.
13. Germann, U. A., Shlyakhter, D., Mason, V. S., Zelle, R. E., Duffy, J. P., Galullo, V., Armistead, D. M., Saunders, J. O., Boger, J., and Harding, M. W. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs, 8: 125-140, 1997.
14. Germann, U. A., Ford, P. J., Shlyakhter, D., Mason, V. S., and Harding, M. W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL-60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs, 8: 141-155, 1997.
15. Ross, D. D. Novel mechanisms of drug resistance in leukemia. Leukemia (Baltimore), 14: 467-473, 2000.
16. Minderman, H., Vanhoefer, U., Toth, K., Minderman, M. D., and Rustum, Y. M. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer (Phila.), 78: 2427-2436, 1996.
17. Marsh, W., Sicheri, D., and Center, M. S. Isolation and characterization of Adriamycin-resistant HL-60 cells which are not defective in the initial accumulation of the drug. Cancer Res., 46: 4053-4057, 1986.
18. Hazlehurst, L. A., Foley, N. E., Gleason-Guzman, M. C., Hacker, M. P., Cress, A. E., Greenberger, L. W., DeJong, M. C., and Dalton, W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res., 59: 1021-1028, 1999.
19. Minderman, H., Suvannasankha, A., O'Loughlin, K. L., Scheper, R. J., Robey, R. W., Bates, S. E., and Baer, M. R. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry, 48: 59-65, 2002.
20. Nakanishi, T., Karp, J. E., Tan, M., Doyle, L. A., Peters, T., Yang, W., Wei, D., and Ross, D. D. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin. Cancer Res., 9: 3320-3328, 2003.
21. Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. O., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., Bloomfield, C. D., and Larson, R. A. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood, 100: 1224-1232, 2002.
22. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J., and Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464, 2001.
23. Gollapudi, S., Kim, C. H., Tran, B. N., Sangha, S., and Gupta, S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL-60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL-60/Tax and P388/ADR cells. Cancer Chem. Pharm., 40: 150-158, 1997.
24. Robey, W. R., Honjo, Y., Van de Laar, A., Miyake, K., Regis, J. T., Litman, T., and Bates, S. E. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta, 1512: 171-182, 2001.
25. Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J., Grever, M. R., Appelbaum, F. R., and Willman, C. L. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94: 1086-1099, 1999.
26. Young, I. T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem., 25: 935-941, 1977.
27. Warner, D. L., and Burke, T. G. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B. Biomed. Sci. Appl., 691: 161-171, 1997.
28. Takenouchi, T., and Munekata, E. Trophic effects of substance P and β-amyloid peptide on dibutyryl cyclic AMP-differentiated human leukemic (HL-60) cells. Life Sci., 56: PL479-484, 1995.
29. Greco, W. R., Park, H. S., and Rustum, Y. M. An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5337, 1990.
30. List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., Shurafa, M., and Appelbaum, F. R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood, 98: 3212-3220, 2001.
31. List, A. F., Spier, C. S., Grogan, T. M., Johnson, C., Roe, D. J., Greer, J. P., Wolff, S. N., Broxterman, H. J., Scheffer, G. L., Scheper, R. J., and Dalton, W. S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87: 2464-2469, 1996.
32. Yanagisawa, T., Newman, A., Coley, H., Renshaw, J., Pinkerton, C. R., and Pritchard-Jones, K. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br. J. Cancer, 80: 1190-1196, 1999.
33. Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J., Harding, M. W., and Von Hoff, D. D. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol., 16: 2964-2976, 1998.
34. Peck, R. A., Hewett, J., Harding, M. W., Wang, Y-M., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H., Atkins, F., and Hawkins, M. J. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor Biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol., 19: 3130-3141, 2001.
35. Bramwell, V. H. C., Morris, D., Ernst, D. S., Hings, I., Blackstein, M., Venner, P. M., Ette, E. I., Harding, M. W., Waxman, A., and Demetri, G. D. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res., 8: 383-393, 2002.
36. Rago, R. P., Einstein, A., Lush, R., Beer, T. M., Ko, Y-J., Henner, W. D., Bubley, G., Merica, E. A., Garg, V., Ette, E., Harding, M. W., and Dalton, W. S. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol., 51: 297-305, 2003.
37. Seiden, M. V., Swenerton, K. D., Matulonis, U., Campos, S., Rose, P., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. W., and Charpentier, D. A Phase II study of the MDR inhibitor biricodar (Incel, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol., 86: 302-310, 2002.
38. Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M. W., and Demetri, G. D. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res., 8: 670-678, 2002.
39. Pallis, M., and Russell, N. P-glycoprotein plays a drug-efflux independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin ceramide apoptotic pathway. Blood, 95: 2897-2904, 2000.